Business Wire

IDEMIA

5.10.2020 18:21:12 CEST | Business Wire | Press release

Share
IDEMIA and Resa Airport Data Systems Were Chosen by VINCI Airports to Come up With a World First: A Wholly Contactless and Biometrics-Based Passenger Experience in Lyon Saint-Exupéry Airport

A world first, remote smartphone-based passenger biometric registration gives passengers a smoother and contactless experience from ID registration until they board. Passenger faces - a genuine Open Sesame throughout the airport - are recorded at home on Mona, Lyon Airport’s smartphone app. Having registered in advance, passengers can put their travel documents away as they pass unhindered through the airport.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201005005759/en/

Passenger registration is secured by a biometric match between their smartphone-based face and scans of their ID document and boarding card. This totally accurate and reliable identity management system that IDEMIA has perfected lets passengers speed through all identity control points.

RESA’s latest automatic and biometric compact gate dubbed Major eGate , which caters for disabled people too, comes with an integrated camera so that passengers can pass through to the security restricted area and then board their plane based merely on facial recognition.

IDEMIA’s system is universal, secure and works on all airline systems thanks to RESA’s IATA-certified CUPPS system. This will be available at Lyon Airport for Transavia and TAP flights to Portugal.

While this new service is subject to formal CNIL1 approval, to date CNIL has recommended it to safeguard passenger data and rights.

IDEMIA Executive VP Identity and Public Safety Philippe Barreau said: “As biometric security solutions expert, we are thrilled to deliver a world first alongside our customers Vinci Airports and Lyon Airport and our partner RESA. This trial harnesses contactless biometric technology that gives users an unrivaled airport experience without letting up one jot on security. This bears out our capacity to constantly innovate to safeguard passenger trust and help pave the way for even smoother and more secure future travel .”

RESA CEO Renaud Willard said: “Current covid restrictions forced us to rethink how to take care of passengers and their interactions with airport security staff and equipment. The biometric trial underway at Lyon Airport was made possible by French industrial collaboration, whereby hi-tech saved the day despite the current pandemic and economic crisis. We have shown here that passengers can pass through airport checks fully contactless and without handing over paper documents while shoring up security to boot.”

Vinci Airports France & Americas Area Director Valérie Vesque-Jeancard said: “We are thrilled to launch MONA today, a world first, at a time when airports need game-changing innovations so they can give passengers an even safer, more enjoyable and personalized experience. I warmly congratulate all staff involved including IDEMIA and RESA people, who managed to overcome tough restrictions these last few months and deliver a great trial in barely a year.”

IDEMIA provides both rapid and safe passenger flow solutions to countless airports around the world and manages 30-plus government border control programs. In 2017, IDEMIA installed a facial recognition-based biometric ID control system in Terminal 4 of Singapore’s Changi Airport, from baggage check-in right through to aircraft boarding, including going airside and border crossing. The Company has regularly conducted facial recognition technology trials to make boarding smoother.

RESA’s expertise lies in introducing biometric technology to authenticate airport security staff, who need to connect to airport IT systems. RESA is currently engaged in introducing such technology on top of existing passenger airport systems. Previously, the firm has conducted several pilot tests including in Singapore and Paris airports.

About IDEMIA

IDEMIA, the global leader in Augmented Identity, provides a trusted environment enabling citizens and consumers alike to perform their daily critical activities (such as pay, connect and travel), in the physical as well as digital space.

Securing our identity has become mission critical in the world we live in today. By standing for Augmented Identity, an identity that ensures privacy and trust and guarantees secure, authenticated and verifiable transactions, we reinvent the way we think, produce, use and protect one of our greatest assets – our identity – whether for individuals or for objects, whenever and wherever security matters. We provide Augmented Identity for international clients from Financial, Telecom, Identity, Public Security and IoT sectors.

With close to 15,000 employees around the world, IDEMIA serves clients in 180 countries.

For more information, visit www.idemia.com / Follow @IDEMIAGroup on Twitter

About RESA

Backed by 30 years of experience and 1,000-plus software programs installed in 62 countries, RESA is one of the world’s top airport and airline systems developers.

The firm is an innovative Vendée-based small business that develops, sells and maintains a broad range of integrated software covering all airport system needs, including passenger check-in and boarding, baggage tracing and reconciliation, passenger tracking, automatic gates, self-service kiosks and biometrics, flight management, resource allocation, billing, statistics, business intelligence and messaging.

__________________________________
1 France’s national authority responsible for data privacy

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

FPT Named an OpenAI Select Partner6.8.2026 02:00:00 CEST | Press release

Global IT corporation FPT today announced that it has been named an OpenAI Select Partner within the OpenAI Partner Network. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260805503787/en/ FPT Named an OpenAI Select Partner The OpenAI Partner Network is a global program for partners to build, sell, and deliver AI solutions with OpenAI. It brings together partners with deep industry expertise, delivery capabilities, and customer relationships while equipping them with resources, enablement, and support to help enterprises adopt OpenAI frontier models and products and turn them into measurable impact. As an OpenAI Select Partner, FPT will continue working with OpenAI to help organizations build, deploy, and scale AI solutions responsibly and effectively. This work will help organizations get more useful work from every token and stronger performance per dollar with GPT‑5.6, while using ChatGPT Work to turn ambitious goals into

U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 16.8.2026 00:10:00 CEST | Press release

Adults Taking ORZEYFUL Experienced Significant and Meaningful Improvements Across the Full Range of Symptoms of Narcolepsy Type 1 (NT1) in Clinical Trials Compared to Those on Placebo As a First-in-Class Orexin Treatment, ORZEYFUL has the Potential to Redefine NT1 Care Beyond Individual Symptoms Takeda is Advancing U.S. Launch Preparations and Expects to Make ORZEYFUL Available Following Completion of the Drug Enforcement Administration (DEA) Scheduling Process Takeda (TSE:4502/NYSE:TAK) announced that the U.S. Food and Drug Administration (FDA) approved ORZEYFUL™ (oveporexton), an oral orexin receptor 2 (OX2R) agonist, for the treatment of narcolepsy type 1 (NT1, narcolepsy with cataplexy) in adults.* The persistent 24-hour nature of NT1 is driven by orexin deficiency and can severely impact people’s lives. As a first-in-class orexin treatment, ORZEYFUL is the only medicine indicated in the U.S. to treat the disease holistically rather than individual symptoms. “The FDA approval of OR

Compass Pathways Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)5.8.2026 22:30:00 CEST | Press release

Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to fourteen newly hired non-executive employees. The equity awards were granted on August 3, 2026 and consisted of options to purchase an aggregate of 139,355 shares and restricted share units or, in the case of employees in the United Kingdom nominal cost options, covering an aggregate of 66,300 shares. The options have an exercise price per share equal to $11.25, the closing price of the Company’s American Depositary Shares on the Nasdaq Global Select Market on the grant date, and will vest over a four-year period with 25% vesting on the first anniversary of the date of the grant and the remaining 75% vesting in equal monthly installments over the three-year period thereafter, subject to each employee’s continued employment. The restricted

Clinilabs Announces Medical Leadership Appointments5.8.2026 16:05:00 CEST | Press release

Bob Dagher, M.D., Named Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., Named Principal Investigator Clinilabs (“Clinilabs LLC”), a global, full-service contract research organization (CRO) specializing in central nervous system (CNS) drug and device development, today announced the appointments of Bob Dagher, M.D., as Chief Medical Officer and Waqar Ahmed Siddiqui, M.D., as Principal Investigator of the Company’s Eatontown, New Jersey Clinical Research Unit (CRU). Dr. Dagher will provide strategic and medical leadership across the organization, while Dr. Siddiqui will lead the execution of research projects at the Company’s CRU. Together, they will support the design, development, and execution of clinical programs for pharmaceutical, biotechnology, and medical device sponsors advancing innovative therapies for psychiatric, neurological, substance use, and rare CNS disorders. “Clinilabs has earned the trust of sponsors by combining deep scientific expertise, medical leadership,

Interactive Brokers Adds Brazilian Futures through Brazil’s B3 Exchange5.8.2026 16:00:00 CEST | Press release

Interactive Brokers (Nasdaq: IBKR), an automated global broker, today announced that eligible clients outside of Brazil can now trade Brazilian futures in addition to equities through the B3 exchange. Interactive Brokers was the first broker to provide international investors with streamlined, low-cost access to B3. Offering Brazilian futures and equities alongside products across more than 170 markets worldwide underscores IBKR’s commitment to broadening global market access and giving clients efficient, cost-effective ways to diversify through a single, unified platform. Access to B3 provides exposure to one of Latin America’s most active and liquid markets, providing long-term growth potential across multiple sectors and another way for investors to pursue emerging market opportunities. "Global investors deserve seamless, low-cost access to the world's most compelling markets, including emerging economies shaping tomorrow's financial landscape," said Milan Galik, Chief Executive Off

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye